|
|
|
|
LEADER |
05314nma a2201417 u 4500 |
001 |
EB002043903 |
003 |
EBX01000000000000001187569 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
220822 ||| eng |
020 |
|
|
|a books978-3-0365-3716-0
|
020 |
|
|
|a 9783036537160
|
020 |
|
|
|a 9783036537153
|
100 |
1 |
|
|a Durazzo, Marilena
|
245 |
0 |
0 |
|a Gastrointestinal Tract Disorders
|h Elektronische Ressource
|
260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
300 |
|
|
|a 1 electronic resource (236 p.)
|
653 |
|
|
|a fecal biomarkers
|
653 |
|
|
|a IgG4-related sclerosing cholangitis
|
653 |
|
|
|a abdominal symptoms
|
653 |
|
|
|a irritable bowel syndrome
|
653 |
|
|
|a colonic transit
|
653 |
|
|
|a cardiovascular risk
|
653 |
|
|
|a pandemic
|
653 |
|
|
|a carotid plaques
|
653 |
|
|
|a primary sclerosing cholangitis
|
653 |
|
|
|a pathophysiology
|
653 |
|
|
|a diabetic gastroparesis
|
653 |
|
|
|a inflammatory bowel diseases
|
653 |
|
|
|a primary care
|
653 |
|
|
|a chronic idiopathic constipation
|
653 |
|
|
|a motility
|
653 |
|
|
|a laryngo-pharyngeal reflux
|
653 |
|
|
|a sleep medicine
|
653 |
|
|
|a hemorrhoidectomy
|
653 |
|
|
|a Emorsan®Gel
|
653 |
|
|
|a therapy
|
653 |
|
|
|a PPI
|
653 |
|
|
|a transmural defect
|
653 |
|
|
|a rebleeding
|
653 |
|
|
|a asthma
|
653 |
|
|
|a eosinophil derived neurotoxin
|
653 |
|
|
|a IgG4-related hepatopathy
|
653 |
|
|
|a Research & information: general / bicssc
|
653 |
|
|
|a infant
|
653 |
|
|
|a diverticulosis
|
653 |
|
|
|a Marfan's syndrome
|
653 |
|
|
|a biologics
|
653 |
|
|
|a celiac disease
|
653 |
|
|
|a gastrointestinal disorders
|
653 |
|
|
|a DA-9701
|
653 |
|
|
|a diabetes
|
653 |
|
|
|a SCORE
|
653 |
|
|
|a tumor necrosis factor α
|
653 |
|
|
|a antibiotic resistance
|
653 |
|
|
|a primary biliary cholangitis
|
653 |
|
|
|a cough
|
653 |
|
|
|a pain
|
653 |
|
|
|a STZ
|
653 |
|
|
|a inflammatory bowel disease
|
653 |
|
|
|a MALT-lymphoma
|
653 |
|
|
|a autoimmune hepatitis
|
653 |
|
|
|a dyssynergic defecation
|
653 |
|
|
|a diverticulitis
|
653 |
|
|
|a etiology
|
653 |
|
|
|a diabetic mouse model
|
653 |
|
|
|a risk factors
|
653 |
|
|
|a gastrointestinal bleeding
|
653 |
|
|
|a ulcerative colitis
|
653 |
|
|
|a vaccines
|
653 |
|
|
|a new oral anticoagulants
|
653 |
|
|
|a human leukocyte antigen
|
653 |
|
|
|a n/a
|
653 |
|
|
|a gastrointestinal motility
|
653 |
|
|
|a slow transit constipation
|
653 |
|
|
|a hemorrhoidal disease
|
653 |
|
|
|a ultrasound
|
653 |
|
|
|a chronic gastritis
|
653 |
|
|
|a wound healing
|
653 |
|
|
|a anemia
|
653 |
|
|
|a social media
|
653 |
|
|
|a tooth erosions
|
653 |
|
|
|a gastric cancer
|
653 |
|
|
|a gastroparesis
|
653 |
|
|
|a Helicobacter pylori
|
653 |
|
|
|a medical students
|
653 |
|
|
|a calprotectin
|
653 |
|
|
|a diverticula
|
653 |
|
|
|a empirical
|
653 |
|
|
|a dietary habit
|
653 |
|
|
|a vitamin K antagonist
|
653 |
|
|
|a public health
|
653 |
|
|
|a dyspepsia
|
653 |
|
|
|a functional dyspepsia
|
653 |
|
|
|a tailored
|
653 |
|
|
|a sleep disorders
|
653 |
|
|
|a Crohn's disease
|
653 |
|
|
|a peptic ulcer disease
|
653 |
|
|
|a anorectal manometry
|
653 |
|
|
|a endoscopic vacuum therapy
|
653 |
|
|
|a autoimmune pancreatitis
|
653 |
|
|
|a gastroesophageal reflux
|
653 |
|
|
|a eradication
|
653 |
|
|
|a Chemistry / bicssc
|
653 |
|
|
|a food allergy
|
653 |
|
|
|a constipation
|
653 |
|
|
|a upper gastrointestinal tract
|
653 |
|
|
|a chest pain
|
700 |
1 |
|
|a Durazzo, Marilena
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
028 |
5 |
0 |
|a 10.3390/books978-3-0365-3716-0
|
856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/5402
|7 0
|x Verlag
|3 Volltext
|
856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/81060
|z DOAB: description of the publication
|
082 |
0 |
|
|a 000
|
082 |
0 |
|
|a 540
|
082 |
0 |
|
|a 612
|
082 |
0 |
|
|a 610
|
082 |
0 |
|
|a 140
|
520 |
|
|
|a Gastrointestinal tract disorders are a wide group of diseases involving both the gastrointestinal tube (esophagus, stomach, small and large intestine) and related organs (liver, pancreas, and gallbladder). These dysfunctions may differ by site, etiology, and severity, going from simple malfunctions to mere diseases. Because of their variety and heterogeneity, gastrointestinal disorders can affect many people and are widespread throughout the population. Therefore, scientific research in this area is facing a great challenge. Better knowledge of gastrointestinal disorders in terms of their pathophysiology, clinical features, and possible complications is necessary for the development of new diagnostic methods and therapeutic strategies. During the last several decades, some scientific developments have already been made, giving more opportunities to these patients. However, much remains to be discovered and to be done to help physicians in their everyday work and to give patients a better prognosis. The present Special Issue aims to highlight recent advances in gastrointestinal tract disorders, focusing on their diagnostic and therapeutic path, evolution, and complications.
|